Chiugray/Senti, Thanks senti for your amazing piece of a thorough analysis of the New Endpoints and their connection to the FDA Effectiveness guidance that FDA proposed last December 2019. Yes, it all signals that the mighty FDA has been with the Powers et al (what a great executive and a visionary LP is) all along in this landmark trial that is going to deliver unprecedented robust results that have never been seen or heard of in the history of cancer space. To add more to your analysis or to close it with the SNO presentation, I want to ask you this. Senti, can you comment on what that LL's Late Breaking SNO Title on Safety and Efficacy signals to you? Is this presentation developed to show the rest of the world that we have met the FDA guidance on Safety & Efficacy? The new endpoints that UK RA agreed upon are better endpoints than the original ones that anybody would agree as the new ones are starting with meeting the gold standard OS which is always harder and longer to achieve. I bet FDA is with us on SAP and New Endpoints, no doubt about it, imo. With doc logic's low lymphatic theory playing behind the even more successful trial in Germany, it is getting more and more interesting.
Market Data 
Markets 
AI
